In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity

Boyum, 1968, Isolation of lymphocytes from human blood. Further observation, Scand. J. clin. Lab. Invest., 21, 31 Brunda, 1986, Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2 activated killer cells, Int. J. Cancer, 37, 787, 10.1002/ijc.2910370522 Damle, 1986, Interleukin-2 activated human killer cells are derived from phenotypically heterogeneous precursors, J. Immun., 137, 2814, 10.4049/jimmunol.137.9.2814 D'Atri, 1988, Comparative studies between in vitro and in vivo effects of human beta interferon on natural killer activity and its relevance to immunochemotherapy, Cancer Immun. Immunother., 27, 163, 10.1007/BF00200022 Dieu, 1979, Augmentation of mouse natural killer cell activity by interferon and interferon inducers, J. Immun., 122, 175, 10.4049/jimmunol.122.1.175 Farace, 1990, Phase I trial with recombinant interleukin-2 (rIL2): immune activation by rIL2 alone or following pretreatment with recombinant interferon-gamma, Clin. exp. Immun., 82, 194, 10.1111/j.1365-2249.1990.tb05426.x Gastl, 1986, A biological approach to optimize interferon treatment in hairy cell leukemia, Immunobiology, 172, 262, 10.1016/S0171-2985(86)80107-3 Gravekamp, 1987, C-myc gene expression and interleukin-2 receptor levels in cloned human CD2+CD3+ and CD2+CD3-lymphocytes, Natn. Immun. Cell Growth Regul., 6, 28 Gresser, 1985, How does interferon inhibit tumor growth?, 6, 93 Grimm, 1982, Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes, J. exp. Med., 155, 1823, 10.1084/jem.155.6.1823 Herberman, 1982, Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes, Cell. Immun., 67, 160, 10.1016/0008-8749(82)90208-8 Iigo, 1988, In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone or in combination with three different types of recombinant interferon, on various syngeneic murine tumors, Cancer Res., 48, 260 Itoh, 1985, Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL2) in collaboration with interferon-gamma (IFN-gamma), J. Immun., 5, 3124, 10.4049/jimmunol.134.5.3124 Klappacher, 1989, Autologous and allogenic natural cell mediated cytotoxicity at the single cell level: divergent effects of interferons and interleukin 2 on binding and lysis, Cancer Lett., 47, 69, 10.1016/0304-3835(89)90179-1 Klein, 1967, Surface IgM kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines, Cancer Res., 28, 1300 Lozzio, 1979, Properties and usefulness of the original K562 human myelogenous leukemia cell line, Leukemia. Res., 3, 363, 10.1016/0145-2126(79)90033-X Neidhardt, 1984, Interferon-alpha therapy of renal cancer, Cancer Res., 44, 4140 Ortaldo, 1991, Mechanistic studies of transforming growth factor-beta inhibition of IL2-dependent activation of CD3-large granular lymphocytic functions. Regulation of IL2R beta (p75) signal transduction, J. Immun., 146, 3791, 10.4049/jimmunol.146.11.3791 Phillips, 1989, Activation of natural killer cells via the p75 interleukin-2 receptor, J. exp. Med., 170, 291, 10.1084/jem.170.1.291 Raefsky, 1985, Studies of interferon as regulator of hemopoietic cell proliferation, J. Immun., 135, 2507, 10.4049/jimmunol.135.4.2507 Ramsdell, 1988, Role of proliferation in LAK cell development, Cancer Immun. Immunother., 26, 139, 10.1007/BF00205607 Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, New Engl. J. Med., 316, 889, 10.1056/NEJM198704093161501 Sone, 1988, Differential effects of recombinant interferons alpha, beta and gamma on induction of human lymphokine (IL-2)-activated killer activity, J.N.C.I., 80, 425 Thorn, 1976, Kinetic analysis of the target cell destruction by effector T cells. Delineation of parameters related to the frequency and lytic efficiency of killer cells, J. Immun., 117, 2213, 10.4049/jimmunol.117.6.2213 Tokuda, 1989, The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity, Cancer Immun. Immunother., 30, 205, 10.1007/BF01665006 Urdal, 1984, Purification and chemical characterization of the receptor for Interleukin-2 from activated human T lymphocytes and from a human T cell lymphoma cell line, 81, 6481 West, 1987, Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, New Engl. J. Med., 316, 898, 10.1056/NEJM198704093161502 Young, 1987, One signal requirement for interferon-gamma production by human large granular lymphocytes, J. Immun., 139, 724, 10.4049/jimmunol.139.3.724